|
Session 126
Poster Abstracts
Clinical Pharmacology of Protease Inhibitors
Tuesday, 1-4 pm
Room: Hall A |
| 765 |
Lopinavir/Ritonavir 500/125 mg Twice-daily + Efavirenz Approximate the Pharmacokinetic Exposure of LPV/r 400/100 mg Twice-daily Administered Alone in Healthy Adult Subjects
Juki Ng*, C Klein, J Xiong, Y L Chiu, T Doan, C Rolle, C Holas, R Stryker, and B Bernstein
Abbott Labs, Abbott Park, IL, US |
| 766a |
Increased Lopinavir Concentrations on Once-daily Tablets as Compared with Capsules and Liquid Formulations
Brookie Best*1, G Rieg2, S Sun1, S Jain1, C Kemper3, C Diamond4, A Hermes5, R Haubrich1, E Daar2, and California Collaborative Treatment Group (CCTG) 585 Team
1Univ of California, San Diego, US; 2Los Angeles Biomed Res Inst at Harbor-UCLA Med Ctr and Univ of California, Los Angeles, US; 3Santa Clara Valley Med Ctr, San Jose, CA, US; 4Univ of California, Irvine, US; and 5Abbott Labs, Abbott Park, IL, US |
| 766b |
Hepatic Transaminase Elevations and Gastrointestinal Intolerance when HIV-negative Healthy Volunteers on Rifampin add Twice-daily Atazanavir ( 300 mg)/Ritonavir ( 100 mg): ACTG Protocol A5213
David Haas*1, S Koletar2, L Laughlin2, M Kendall3, C Suckow3, J Gerber4, A Zolopa5, R Bertz6, M Child6, E Acosta7, and the A5213 Study Team
1Vanderbilt Univ Sch of Med, Nashville, TN, US; 2Ohio State Univ, Columbus, US; 3Statistical and Data Analysis Ctr, Harvard Sch of Publ Hlth, Boston, MA, US; 4Univ of Colorado Hlth Sci Ctr, Denver, US; 5Stanford Univ, Palo Alto, CA, US; 6Bristol-Myers Squibb, Princeton, NJ, US; and 7Univ of Alabama at Birmingham, US |
| 767 |
Pharmacokinetic Interaction between Tipranavir/Ritonavir and Rosuvastatin
Paul Pham*1, L Lee1, E Fuchs1, P Barditch-Crovo1, K Carson1, C Radebaugh1, S Everts1, P Piliero2, and C Flexner1
1Johns Hopkins Univ, Baltimore, MD, US and 2Boehringer Ingelheim Pharma, Inc, Ridgefield, CT, US |
| 768 |
Inhibitory Quotient as a Predictor of Virological Response to Darunavir-based Salvage Regimens
Jose Molto*1, J Santos1, N Perez-Alvarez1,2, S Cerdeno3, C Miranda1, S Khoo4, L Else4, J Llibre1, M Valle5, and B Clotet1,3
1Hosp Univ Germans Trias i Pujol and Fndn Lluita contra la SIDA, Badalona, Spain; 2Univ Politecnica de Barcelona, Spain; 3Hosp Univ Germans Trias i Pujol and Fndn irsiCaixa, Badalona, Spain; 4Univ of Liverpool, UK; and 5Hosp de la Santa Creu i Sant Pau, Barcelona, Spain |
| 769 |
Pharmacokinetic/Pharmacodynamic Analyses of Once-daily Darunavir in the ARTEMIS Study
Vanitha Sekar*1, C Vanden Abeele2, B Van Baelen2, P Vis3, L Lavreys2, M De Pauw2, S Dincq2, T Vangeneugden2, S Spinosa-Guzman2, and R Hoetelmans2
1Tibotec Inc, Yardley, PA, US; 2Tibotec, Inc, Mechelen, Belgium; and 3Exprimo NV, Mechelen, Belgium |
| 770 |
Switch from Ritonavir-boosted to Unboosted Atazanavir Guided by Monitoring Atazanavir Concentrations in a Clinical Setting
Sonia Rodriguez-Novoa*1, J Morello1, P Barreiro2, I Maida2, P Garcia-Gasco2, G Gonzalez-Pardo1, A Parra1, I Jimenez-Nacher1, and V Soriano2
1Hosp Carlos III, Madrid, Spain and 2Hosp Carlos III, Madrid, Spain |
| 771 |
Influence of the Orosomucoid Polymorphism on Amprenavir Pharmacokinetics in HIV-infected Patients: ANRS104 Trial
A Barrail-Tran1, C Cosson1, G Raguin2, G Chene3, P M Girard4, and Anne-Marie Taburet*1
1Hosp Bicetre, Le Kremlin Bicetre, France; 2Croix St Simon Hosp, Paris, France; 3INSERM U593, Bordeaux, France; and 4Hosp St Antoine, Paris, France |
| 772 |
Association between Blips and Subtherapeutic Antiretroviral Plasma Levels
S Fiorante1, Sonia Rodriguez Novoa*2, P Garcia Gasco1, J Morello2, F Blanco1, G Gonzalez Pardo2, A Parra2, I Jimenez Nacher2, J Gonzalez Lahoz1, and V Soriano1
1Hosp Carlos III, Madrid, Spain and 2Hosp Carlos III, Madrid, Spain |
| 773 |
Integrating Pharmacokinetics and Antiretroviral Resistance Testing in Clinical HIV-1 Management
Jennifer King*1, I Ofotokun2, M Rivas2, V Johnson1,3, and E Acosta1
1Univ of Alabama at Birmingham, US; 2Emory Univ Sch of Med, Atlanta, GA, US; and 3Birmingham VAMC, AL, US |
|
